Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor

被引：33

作者：

Bougas D.A. ^{[1
]}

Mitsogiannis I.C. ^{[1
]}

Mitropoulos D.N. ^{[1
]}

Kollaitis G.C. ^{[1
]}

Serafetinides E.N. ^{[1
]}

Giannopoulos A.M. ^{[1
]}

机构：

[1] Department of Urology, University of Athens, Medical School, 115 27 Athens

来源：

International Urology and Nephrology | 2004年 / 36卷 / 4期

关键词：

Clean intermittent self catheterisation; Detrusor hypocontractility; Distigmine bromide; Urodynamics;

D O I：

10.1007/s11255-004-0847-8

中图分类号：

学科分类号：

摘要：

Purpose: The aim of this study was to assess the clinical efficacy of distigmine bromide, an anti-cholinesterase agent, deemed to improve detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity. Materials and methods: A total of 27 patients (11 men and 16 women) with poor detrusor function were included in the study. The diagnosis was established using pressure-flow studies. All patients received distigmine bromide at a dose of 5 mg three times daily for 4 weeks and re-attended for a follow-up urodynamic investigation. The results of baseline pressure-flow studies were compared to those after completion of treatment. Results: Treatment with distigmine bromide resulted in a statistically significant reduction of residual volume and percent residual volume, obviating the need for intermittent self-catheterisation in 11 patients. In addition, maximum flow rate and detrusor pressure at maximum flow increased, although not significantly. The drug was generally well tolerated by the majority of patients. Conclusion: Distigmine bromide shows clinical efficacy in patients with poor detrusor function and may therefore be used alternatively in selected cases. © 2004 Kluwer Academic Publishers.

引用

页码：507 / 512

页数：5

共 11 条

[1]

Abrams P., Cardozo L., Fall M., Et al., The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society, Neurourol. Urodyn., 21, 2, pp. 167-178, (2002)

[2]

Lapides J., Diokno A.C., Silber S.T., Lowe B.S., Clean intermittent self catheterisation in the treatment of urinary tract disease, J. Urol., 107, 3, pp. 458-461, (1972)

[3]

Diokno A.C., Sonda L.P., Hollander J.B., Lapides J., Fate of patients started on intermittent self-catheterisation therapy 10 years ago, J. Urol., 129, 6, pp. 1120-1122, (1983)

[4]

Maynard F.M., Diokno A.C., Clean intermittent catheterisation for spinal cord injury patients, J. Urol., 128, 3, pp. 477-480, (1982)

[5]

Maynard F.M., Diokno A.C., Urinary infections and complications during clean intermittent catheterisation following spinal cord surgery, J. Urol., 132, 5, pp. 943-946, (1984)

[6]

Perkash I., Giroux J., Clean intermittent catheterisation in spinal cord injury patients: A follow-up study, J. Urol., 149, 5, pp. 1068-1071, (1993)

[7]

Tanaka Y., Masumori N., Itoh N., Et al., Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate, Urology, 57, 2, pp. 270-274, (2001)

[8]

Philp N.H., Thomas D.G., The effect of distigmine bromide on voiding in male paraplegic patients with reflex micturition, Br. J. Urol., 52, 6, pp. 492-496, (1980)

[9]

Smith P.H., Cook J.B., Prasad E.W.M., The effect of distigmine bromide on bladder function after recent complete spinal cord injury, Br. J. Urol., 46, 2, pp. 187-192, (1974)

[10]

Vree T.B., Waitzinger J., Hammermaier A., Radhofer-Welte S., Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine bromide in healthy volunteers, Int. J. Clin. Pharmacol. Ther., 37, 8, pp. 393-403, (1999)

← 1 2 →